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Stress-related neuropsychiatric disorders,
such as depression and anxiety, are debilitating diseases that impose a great cost for
patients, their families and society. Current
first-line treatments for major depressive disorder and anxiety disorders target serotonergic neurotransmission, but the female-biased
prevalence of these disorders has long suggested a role for hormones in the etiology and
treatment of these diseases. Perhaps the most
common hypothesis in this regard is that
ovarian hormones promote resilience whereas
declining hormone levels (e.g., after childbirth or menopause) increase susceptibility
to depressive disorders. In fact, administering
the potent estrogen, estradiol, as hormone
therapy to perimenopausal women improves
mood [1] . Moreover, polymorphisms in the
genes for estrogen receptor (ER) α and the
enzyme that metabolizes serotonin are both
independently linked to depressive symptoms in menopausal women [2] . In addition
to serotonin, times of endocrine flux may
also contribute to vulnerability by causing
dysregulation in oxytocin (OT) signaling.
Methylation of the OT receptor (OTR) gene
is associated with diagnoses of anxiety and/
or depression in older women [3] and postpartum women [4] . The relationship between
OT and affect may be enhanced during these
periods because estradiol regulates both
OT and OTR through activation of ER-β
and -α, respectively [5] . Together these data
implicate gonadal steroid hormones, such as
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estradiol, and its cognate receptors as integral
modulators of genes that regulate mood and
anxiety. This further raises the possibility of
harnessing hormone-sensitive brain networks
as a therapeutic intervention for patients with
diseases involving mood and affect. In this
article, we will discuss two potential neural
networks, the serotonergic system and the
OTergic system, that could prove to be particularly useful targets for endocrine therapy.
Principle among antidepressant drug therapies are selective serotonin reuptake inhibitors (SSRIs), which prolong serotonergic
signaling by increasing the time serotonin
spends in synapses. Estrogenic hormones
have been shown to mediate the efficacy of
serotonin-related treatments. The anxiolytic
effects of SSRI treatment are prevented by
ovariectomy and are restored by estrogen
replacement [6] , and estrogen treatment augments the antidepressant effects of SSRIs in
ovariectomized rats [7] . These results may be
attributed to a serotonergic coordination of
the anxiolytic and antidepressant effects of
estrogen, as estradiol increases the expression
of the serotonin transporter and serotonin-1B
autoreceptor and blocking the serotonin-1B
autoreceptor prevents the anxiolytic effects
of estrogen [6,8] . Moreover, SSRI treatment
itself can alter the endocrine state of patients.
SSRIs are known to be endocrine disruptors
and can reduce fertility, reduce androgens
and increase the estrogen:androgen ratio
in adrenocortical cell cultures, possibly by
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increasing aromatase activity [9] . This further strengthens the need for understanding the relationship
between the serotonin system and endocrine systems.
Efficacious treatments are needed for distinct populations (e.g., women who hope to become mothers
and perimenopausal women), and perhaps targeting
identified hormone-sensitive neural circuits directly
rather than providing systemic treatments could be an
a lternative strategy.
Serotonergic brain regions, such as the dorsal raphe,
are exquisitely sensitive to hormones. Treating nonhuman primates with estradiol increases a number of
genes and/or proteins that enhance serotonin neurotransmission, including TPH2, serotonin-1A receptors
and serotonin-1B receptors [10,11] . ERs are expressed by
serotonergic and nonserotonergic neurons of the dorsal
raphe. However, estrogens are certainly not the only
hormones that affect serotonergic neurotransmission.
The neurons of the dorsal raphe also express high levels
of glucocorticoid receptors, progesterone receptors and
OTRs. Of these, the OTR is of particular interest. In
fact, administering OT to healthy men has dramatic
effects on serotonin signaling in the brain. By visualizing binding of a serotonin-1a receptor antagonist,
Mottolese et al. showed that OT reduces extracellular serotonin in the dorsal raphe and several of its
targets, including the amygdala. Administering OT to
men increased between-region correlation in antagonist binding in the dorsal raphe and the amygdala,
which suggests enhanced cross-talk between the two
regions [12] . These findings are of particular importance
because while both serotonin and OT were known to
act in the amygdala to mediate behavioral responses
to threatening stimuli, it was previously unknown
whether the two systems operated independently or
could interact.
In addition to being a potent regulator of serotonin
signaling, the neural OT system could be a therapeutic target itself. While OT is classically known for its
roles in reproduction [13] and social behavior [14] , it
also modulates mood and affect. Preclinical research
has reported both anxiolytic [15] and antidepressive [16]
effects of OT. Moreover, electroconvulsive therapy
(ECT) increases neurophysin I, which is stimulated by
estrogen and released stoichiometrically with OT, and
the treatment-induced increase is greater in patients for
whom ECT reduced depressive symptoms than those
who were not relieved by ECT [17] . In contrast, a more
recent report indicated that while depressed patients
had lower levels of circulating OT than nonpatients,
neither antidepressant drugs nor ECT had any effect
on serum OT levels [18] . Patients with mood disorders
may show abnormalities in OT function, as brain
tissue from depressed human subjects indicates an

10.4155/fsoa-2017-0060

elevation of OT mRNA in the paraventricular nucleus
of the hypothalamus, a major site of OT synthesis [19]
for oxytocin neurotransmission to forebrain sites that
regulate behaviors [20] . This finding has also been
observed in a preclinical model of depression known
as the chronic stress model, as exposure to the chronic
stress paradigm has induced an upregulation of OT
mRNA within the paraventricular nucleus of the male
rat [21] . Thus, it appears that affective disorders may be
associated with dysregulated OT signaling.
The effects of OT on mood are believed to stem
from this hormone’s mediation of two distinct pathways: the serotonergic system and the hypothalamo–
pituitary–adrenal (HPA) axis. Approximately, a fourth
of serotonergic neurons in the dorsal raphe express
OTR and, conversely, a third of OTR expressing
neurons in the raphe are serotonergic. These neuroanatomical results are consistent with the observation that although OT acts in the raphe to reduce
anxiety [22] , this may not be due to OT action directly
on serotonergic neurons because knocking out OTR
from serotonergic cells had no effect on anxiety-like
behavior [23] . These data suggest that OT’s anxiolytic effects in the raphe may instead be coordinated
by nonserotonergic neurons. The HPA axis, a major
regulator of neuroendocrine stress responsivity, frequently shows dysregulation in patients with mood
disorders [24] , where depressed patients are unable to
respond to glucocorticoids with negative feedback
inhibition in a dexamethasone:corticotropin releasing
hormone suppression test. While central OT largely
has a suppressive effect on the HPA axis [25] , the nature
of OT’s influence on this axis appears to be site-dependent since OT reportedly acts on the anterior pituitary
gland to augment HPA axis activity through enhancing the secretogoue activity of corticotropin releasing
hormone receptor CRFR1 [26] . Given this divergence
in OT’s effects on HPA axis activity, any treatment targeting the OT system to alleviate affective symptoms
must consider its sites of action.
Despite the anti-anxiety and antidepressive qualities
of OT, its clinical utility has been limited by its inability to penetrate the blood–brain barrier. Intranasal OT
administration has shown potential in reducing symptoms of anxiety and, to a lesser extent, depression when
delivered in high enough concentrations [27] . However,
further investigation is still required to determine
the efficacy of this treatment. Research using OTR
agonists is currently limited, and while intracerebroventricular administration of the agonist carbetocin
decreases anxiety-like behavior in the mouse, this
compound has no effects on behavior when administered peripherally [28] , providing further support for
the hypothesis that the blood–brain barrier prevents
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peripheral OT manipulations from being effective.
Thus, there is currently no known OTR agonist with
therapeutic potential for the treatment of affective
disorders. One promising means for indirectly activating the OT system is through treatment with estrogens. Estradiol upregulates expression of both OT
and OTR [5] . If the OT system could be targeted by
a circuit-specific endocrine therapy such as a selective
ER modulator, it may be possible to induce a central
OT response to peripherally administered treatments.
Unfortunately, one caveat is that current compounds
would not be feasible as they would likely cause off
target effects in other brain regions.
Serotonin and OT are two of several neuromodulators with strong links to affect and mood disorders in
humans and with robust literatures indicating involvement in nonhuman animal models of depression- and
anxiety-related behaviors. Both of these neurotransmitter systems are sensitive to regulation by gonadal
hormones, particularly estradiol. The development of
approaches that can target ER activity with restricted
effects to estrogen sensitive neural circuits in specific
brain nuclei could open a new therapeutic avenue.
Although recent advances have been able to deliver
estradiol specifically to the brain [29] , thereby bypassing

potential peripheral side effects, brain region or circuit
level specificity of such a targeted approach is beyond
the reach of today’s technology. The race to develop
brain region or circuit-specific therapeutics could one
day yield many beneficial treatment avenues for pharmaceutical exploration.
Author contributions
MA Holschbach and AP Borrow wrote the article with support
and assistance from RJ Handa.

Financial & competing interests disclosure
Funding from NIH via R01 NS039951 and MH082900 supported this work. The authors have no other relevant affiliations or financial involvement with any organization or entity
with a financial interest in or financial conflict with the subject
matter or materials discussed in the manuscript apart from
those disclosed.
No writing assistance was utilized in the production of this
manuscript.

Open access
This work is licensed under the Creative Commons Attribution
4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

240–250 (2016).

References
Papers of special note have been highlighted as:
• of interest; •• of considerable interest

8

Donner N, Handa RJ. Estrogen receptor beta regulates
the expression of tryptophan-hydroxylase 2 mRNA
within serotonergic neurons of the rat dorsal raphe nuclei.
Neuroscience 163(2), 705–718 (2009).

1

Schmidt PJ, Rubinow DR. Sex hormones and mood in the
perimenopause. Ann. NY Acad. Sci. 1179, 70–85 (2009).

2

Rozycka A, Slopien R, Slopien A et al. The MAOA, COMT,
MTHFR and ESR1 gene polymorphisms are associated with
the risk of depression in menopausal women. Maturitas 84,
42–54 (2016).

9

Hansen CH, Larsen LW, Sorensen AM, Halling-Sorensen
B, Styrishave B. The six most widely used selective serotonin
reuptake inhibitors decrease androgens and increase estrogens
in the H295R cell line. Toxicol. In vitro 41, 1–11 (2017).

3

Chagnon YC, Potvin O, Hudon C, Preville M. DNA
methylation and single nucleotide variants in the brainderived neurotrophic factor (BDNF) and oxytocin receptor
(OXTR) genes are associated with anxiety/depression in
older women. Front. Genet. 6, 230 (2015).

10

Bethea CL, Lu NZ, Gundlah C, Streicher JM. Diverse
actions of ovarian steroids in the serotonin neural system.
Front. Neuroendocrinol. 23(1), 41–100 (2002).

11

Bethea CL, Kohama SG, Reddy AP, Urbanski HF. Ovarian
steroids regulate gene expression in the dorsal raphe of old
female macaques. Neurobiol. Aging 37, 179–191 (2016).

12

Mottolese R, Redoute J, Costes N, Le Bars D, Sirigu A.
Switching brain serotonin with oxytocin. Proc. Natl Acad.
Sci. USA 111(23), 8637–8642 (2014).

13

Borrow AP, Cameron NM. The role of oxytocin in mating
and pregnancy. Horm. Behav. 61(3), 266–276 (2012).

14

Lukas M, Toth I, Reber SO, Slattery DA, Veenema AH,
Neumann ID. The neuropeptide oxytocin facilitates prosocial behavior and prevents social avoidance in rats and
mice. Neuropsychopharmacology 36(11), 2159–2168 (2011).

15

Bale TL, Davis AM, Auger AP, Dorsa DM, McCarthy
MM. CNS region-specific oxytocin receptor expression:
importance in regulation of anxiety and sex behavior. J.
Neurosci. 21(7), 2546–2552 (2001).

4

5
6

7

Kimmel M, Clive M, Gispen F et al. Oxytocin
receptor DNA methylation in postpartum depression.
Psychoneuroendocrinology 69, 150–160 (2016).
Borrow AP, Handa RJ. Estrogen receptors modulation of
anxiety-like behavior. Vitam. Horm. 103, 27–52 (2017).
Charoenphandhu J, Teerapornpuntakit J, Nuntapornsak A,
Krishnamra N, Charoenphandhu N. Anxiety-like behaviors
and expression of SERT and TPH in the dorsal raphe
of estrogen- and fluoxetine-treated ovariectomized rats.
Pharmacol. Biochem. Behav. 98(4), 503–510 (2011).
Ibrahim WW, Safar MM, Khattab MM, Agha AM. 17betaEstradiol augments antidepressant efficacy of escitalopram in
ovariectomized rats: neuroprotective and serotonin reuptake
transporter modulatory effects. Psychoneuroendocrinology 74,

future science group

Editorial

www.future-science.com

10.4155/fsoa-2017-0060

Editorial

Holschbach, Borrow & Handa

16

Yan Y, Wang Y-L, Su Z et al. Effect of oxytocin on the
behavioral activity in the behavioral despair depression rat
model. Neuropeptides 48(2), 83–89 (2014).

17

Scott AI, Whalley LJ, Bennie J, Bowler G. Oestrogenstimulated neurophysin and outcome after electroconvulsive
therapy. Lancet 1(8495), 1411–1414 (1986).

aggression without affecting anxiety-like behavior in male
mice only. Genes Brain Behav. 14(2), 167–176 (2015).
24

Watson S, Mackin P. HPA axis function in mood disorders.
Psychiatry 5(5), 166–170 (2006).

25

Neumann ID, Krömer SA, Toschi N, Ebner K. Brain
oxytocin inhibits the (re)activity of the hypothalamo–
pituitary–adrenal axis in male rats: involvement of
hypothalamic and limbic brain regions. Regul. Pept. 96(1–2),
31–38 (2000).

26

Gibbs D, Vale W, Rivier J, Yen S. Oxytocin potentiates the
ACTH-releasing activity of CRF (41) but not vasopressin.
Life Sci. 34(23), 2245–2249 (1984).

27

Hofmann SG, Fang A, Brager DN. Effect of intranasal
oxytocin administration on psychiatric symptoms: a metaanalysis of placebo-controlled studies. Psychiatry Res. 228(3),
708–714 (2015).

18

Ozsoy S, Esel E, Kula M. Serum oxytocin levels in patients
with depression and the effects of gender and antidepressant
treatment. Psychiatry Res. 169(3), 249–252 (2009).

19

Meynen G, Unmehopa UA, Hofman MA, Swaab DF,
Hoogendijk WJG. Hypothalamic oxytocin mRNA
expression and melancholic depression. Mol. Psychiatry 12(2),
118–119 (2007).

20

Knobloch HS, Charlet A, Hoffmann LC et al. Evoked axonal
oxytocin release in the central amygdala attenuates fear
response. Neuron 73(3), 553–566 (2012).

21

Babygirija R, Bulbul M, Yoshimoto S, Ludwig K, Takahashi
T. Central and peripheral release of oxytocin following
chronic homotypic stress in rats. Auton. Neurosci. 167(1–2),
56–60 (2012).

28

Mak P, Broussard C, Vacy K, Broadbear JH. Modulation
of anxiety behavior in the elevated plus maze using peptidic
oxytocin and vasopressin receptor ligands in the rat. J.
Psychopharmacol. 26(4), 532–542 (2012).

22

Yoshida M, Takayanagi Y, Inoue K et al. Evidence that
oxytocin exerts anxiolytic effects via oxytocin receptor
expressed in serotonergic neurons in mice. J. Neurosci. 29(7),
2259–2271 (2009).

29

Prokai L, Nguyen V, Szarka S et al. The prodrug DHED
selectively delivers 17β-estradiol to the brain for treating
estrogen-responsive disorders. Sci. Transl. Med. 7(297),
297ra113 (2015).

23

Pagani JH, Williams Avram S, Cui Z et al. Raphe serotonin
neuron-specific oxytocin receptor knockout reduces

10.4155/fsoa-2017-0060

Future Sci. OA (2017) 3(4), FSO222

future science group

